Ruben Mesa/LinkedIn
Aug 31, 2026, 14:28
Ruben Mesa: FDA Approves Ropeginterferon Alfa-2b for Essential Thrombocythemia
Ruben Mesa, President of Cancer National Service Line at Advocate Health, shared a post on LinkedIn:
“Honored to have been involved with (as PI of the Global Surpass ET trial) the now FDA approval of ROPEG INF a2b for patients with Essential Thrombocythemia.
This is the first approval in over 30 years for patients with this myeloid neoplasm MPN and helps decrease disease associated risks, symptoms, and modifies the underlying clone.”
Stay updated with Hemostasis Today.
-
Oct 16, 2026, 18:12Adil Nawaz: Extended Dual Antiplatelet Therapy After Coronary Stenting
-
Oct 16, 2026, 17:50Elad Asher։ STORM-PE Shows Functional Benefits of Thrombectomy
-
Oct 16, 2026, 17:32Shruthi Narayan: STORM-PE and STRIKE-PE Studies Advance Understanding of Recovery After Pulmonary Embolism
-
Oct 16, 2026, 17:22Wolfgang Miesbach։ What a Near-Perfect FISH Score Fails to See
-
Oct 16, 2026, 17:06Troels Wienecke: Connecting Myeloproliferative Disease and Ischemic Stroke
-
Oct 16, 2026, 17:03Only 5 Days Left to Submit Your Research for EAHAD 2027
-
Oct 16, 2026, 16:48Abdul Rahman: Reticulocyte Count and Bone Marrow Activity
-
Oct 16, 2026, 16:44DOAC Adherence in Stroke Patients With Atrial Fibrillation – International Journal of Stroke
-
Oct 16, 2026, 16:22Shannon Farmer: Driving Patient Blood Management Forward in Australia and New Zealand